Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ImmunoCellular Therapeutics has decided to conduct its Phase II clinical trial of ICT-107 in more than 20 sites following the receipt of Institutional Review Board (IRB) approval for 21 sites.
Subscribe to our email newsletter
ICT-107 is the company’s dendritic cell based cancer vaccine candidate that targets multiple tumor antigens for the treatment of glioblastoma multiforme (GBM).
ImmunoCellular’s double-blind, placebo-controlled, 2:1 randomized Phase 2 trial is intended to investigate the safety and efficacy of ICT-107 in patients with newly diagnosed GBM.
ImmunoCellular president and CEO Manish Singh said they look forward to generating data in support of the safety and efficacy of ICT-107 in the treatment of GBM and to further support the promising outcomes reported in our Phase I study.